United States:
FDA Determines Regulatory Review Periods For Drug And Biologic Patents
To print this article, all you need is to be registered or login on Mondaq.com.
In recent issues of the Federal Register, FDA published
determinations regarding the regulatory review periods for patent
extensions of BRILINTA and YERVOY.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
